Maurizio Martelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients	EUROPEAN JOURNAL OF CANCER	2021
Reduced transmission of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic	JAC-ANTIMICROBIAL RESISTANCE	2021
Relapsed/Refractory Multiple Myeloma Patients. A Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy	BLOOD	2021
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib	CANCERS	2021
Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome	HAEMOPHILIA	2021
High basal maximal standardized uptake value (Suvmax) in follicular lymphoma identifies patients with a low risk of long-term relapse	CANCERS	2021
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial	THE LANCET. HAEMATOLOGY	2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience	LEUKEMIA & LYMPHOMA	2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects	BRITISH JOURNAL OF HAEMATOLOGY	2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2021
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia	BLOOD	2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma	BLOOD ADVANCES	2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment	BLOOD ADVANCES	2021
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA	BLOOD ADVANCES	2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia	EXPERT OPINION ON INVESTIGATIONAL DRUGS	2021